You are here

  • Home
  • Archive
  • Volume 98, Issue 3
  • Timing of primary syphilis treatment and impact on the development of treponemal antibodies: a cross-sectional clinic-based study

Article Text

Article menu
Download PDFPDF
Clinical
Original research
Timing of primary syphilis treatment and impact on the development of treponemal antibodies: a cross-sectional clinic-based study
  1. Janet M Towns1,2,
  2. David E Leslie3,
  3. Ian Denham1,
  4. Francesca Azzato3,
  5. Theo Karapanagiotidis3,
  6. Deborah A Williamson4,5,6,
  7. Stephen R Graves7,
  8. Christopher K Fairley1,2,
  9. Melanie Bissessor1,
  10. Eric P F Chow1,2,8,
  11. Lei Zhang1,2,9,10,
  12. Marcus Y Chen1,2
  1. 1 Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia
  2. 2 Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia
  3. 3 Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
  4. 4 Melbourne Diagnostic Unit Public Health Laboratory, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
  5. 5 Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
  6. 6 Department of Microbiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
  7. 7 Australian Rickettsial Reference Laboratory, Barwon Health, Geelong, Victoria, Australia
  8. 8 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
  9. 9 China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, People's Republic of China
  10. 10 Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou, People's Republic of China
  1. Correspondence to Dr Janet M Towns, Melbourne Sexual Health Centre, Carlton, VIC 3053, Australia; jtowns{at}mshc.org.au

Abstract

Background Serology is negative in a proportion of primary syphilis cases where Treponema pallidum PCR testing is positive. We aimed to identify discordant, T. pallidum PCR-positive, serology-negative primary syphilis cases and any clinical or laboratory factors associated with failure to subsequently seroconvert.

Methods Serodiscordant primary syphilis cases that were T. pallidum PCR-positive and serology-negative (including rapid plasma reagin, T. pallidum particle agglutination, T. pallidum enzyme immunoassay or T. pallidum chemiluminescence assay) were identified from the Melbourne Sexual Health Centre electronic records between April 2011 and December 2019. Clinical and laboratory associations were examined.

Results There were 814 primary syphilis cases in the study period and 38 (4.7%) were serodiscordant, 35 in men who have sex with men. Thirty-two had follow-up serology performed a median of 24 days later, of which 16 (50%) seroconverted, mostly (81%) within 6 weeks. Failure to seroconvert was significantly associated with treatment on day 1. Of the 12 cases treated on day 1, 10 (83%) failed to seroconvert compared with 6 of 20 (30%) among those who were treated after day 1.

Discussion Earlier treatment of primary syphilis can prevent the development of serological markers. T. pallidum PCR can identify primary syphilis lesions before the development of serological markers and improve diagnosis of early primary syphilis lesions. Serology alone will miss a proportion of primary syphilis infections and should be repeated if a diagnosis of syphilis is being considered.

  • syphilis
  • diagnosis
  • PCR

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

https://doi.org/10.1136/sextrans-2020-054739

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplementary information.

    View Full Text

    Footnotes

    • Handling editor Henry John Christiaan de Vries

    • Twitter @drdebwilliamson, @EricPFChow

    • Deceased DEL died on 4 July 2018

    • Contributors DEL conceived and designed the study and drafted the original manuscript. FA performed the laboratory testing. Data analysis was performed by JMT. JMT and MYC drafted the final version of the manuscript. EPFC and LZ provided advice on statistical analysis. All authors except DEL (deceased in 2018) critically reviewed the manuscript for important intellectual content and approved the final version.

    • Funding JMT is supported by a Monash University Research Training Program Stipend and by a Royal Australasian College of Physicians Foundation Research Entry Scholarship. DW and EPFC are supported by an Australian NHMRC Emerging Leadership Investigator Grant (GNT1174555 and GNT1172873, respectively). CKF is supported by an Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grant (GNT1172900).

    • Competing interests MYC has received donated materials from SpeeDx.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.